• HTA171 Are Global Trials Good Enough to Support the Reimbursement of a New Technology in Asia? A Review of Asian HTA Submissions

    Dec 1, 2022, 00:00

  • EE77 Cost-Effectiveness Analysis of Pharmacogenetic-Guided Treatment in Drug Resistant Depression

    Dec 1, 2022, 00:00

  • EE90 Are There Specificities for Assessing Quality of Life and Utilities in Rare Diseases for Economic Evaluation in Fran A Case Study of Published CEESP Opinions

    Dec 1, 2022, 00:00

  • HPR42 A New Organizational Model to Manage Chronic Diseases With Digital Medicine Tools

    Dec 1, 2022, 00:00

  • HTA248 Could Early Scientific Advice Have Improved Outcomes in Cost-Effectiveness Markets?

    Dec 1, 2022, 00:00

  • RWD92 Persistence and Patterns of Exposure to Omalizumab in Patients With Asthma in France Between 2009 and 2019 (SOLAIR Study)

    Dec 1, 2022, 00:00

  • HTA198 The Influence of the Claimed Benefit Versus the Given Benefit on the Negotiated Rebate During the German Health Technology Assessment

    Dec 1, 2022, 00:00

  • EE44 Pain Therapy With Spinal Cord Stimulation (SCS) in Patients With Painful Diabetic Neuropathy (PDN): Results of a Budget Impact Model

    Dec 1, 2022, 00:00

  • EE37 Cost-Utility Analysis of Elecsys Gaad Algorithm Versus Ultrasound Plus -Fetoprotein (AFP) for HCC Surveillance in Patients With Compensated Liver Cirrhosis in the United Kingdom (UK)

    Dec 1, 2022, 00:00

  • EE156 Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure (HF) with Preserved Ejection Fraction (HFPEF) in France, Based on Emperor-Preserved Clinical Trial

    Dec 1, 2022, 00:00

  • PCR229 Two Simple Methods for Daily Measuring Compliance With Oral Nutritional Supplements in the Community: Electronic Self-Report Method Versus Image-Based Method

    Dec 1, 2022, 00:00

  • HSD97 Automated Versus Manual Prior Authorization for Type 2 Diabetes Mellitus Drugs: A Retrospective Study From Israel

    Dec 1, 2022, 00:00

  • EE202 Estimating the Public Health Benefits of Preventing Herpes Zoster and Postherpetic Neuralgia in Greece by Zoster Vaccines: A Modelling Study

    Dec 1, 2022, 00:00

  • PCR16 Variables Associated With Carer Quality of Life in England Using a Large, National Data Set

    Dec 1, 2022, 00:00

  • CO3 Sensitivity to Change of the Oxford Participation and Activities Questionnaire in People With Parkinson’s

    Dec 1, 2022, 00:00

  • HPR57 Do Favourable Access Conditions and Policies for Biosimilars Result in Increased Consumption in the EU4 and the UK?

    Dec 1, 2022, 00:00

  • P42 Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation

    Dec 1, 2022, 00:00

  • EE554 Costs Comparison Between Dupilumab and Omalizumab in the Treatment of Severe Allergic Asthma in the Brazilian Private Healthcare Perspective

    Dec 1, 2022, 00:00

  • EE392 Cost-Effectiveness Analysis of Atrial Fibrillation Screening for a 50–65-Year-Old Population With Elevated Stroke Risk

    Dec 1, 2022, 00:00

  • RWD77 Validation of Prevalence and Incidence Rates for Six Different Diseases Using Livingstone: An Online, Automated Analytical Platform

    Dec 1, 2022, 00:00

  • HSD92 Operational Savings Generated in an Integrated Care Clinic for Immune-Mediated Skin Disorders

    Dec 1, 2022, 00:00

  • EE204 Cost-Effectiveness of Everolimus Combination Therapy in Patients After Liver Transplantation Focusing on Cancer Risk: A Markov Model Using Real-World Data

    Dec 1, 2022, 00:00

  • PCR1 Comparison of Infant’s CRY/Fuss Report Between Parental Perception and Recording Analysis, and Its Potential Implications on Parental Mental Health

    Dec 1, 2022, 00:00

  • HSD63 Characteristics and Treatment Patterns of Patients Initiating Cladribine Tablets: A U.S. Commercial and Medicare Advantage Prescription Drug Claims Analysis

    Dec 1, 2022, 00:00

  • MSR109 Can Jointly Modelling PFS and OS With Mixture Cure Models Overcome Data Immaturity Problems?

    Dec 1, 2022, 00:00

  • PCR258 Citizens’ Preferences for Robot-Assisted Hip Replacement: Results of an Online Cross-Sectional Study in Hungary

    Dec 1, 2022, 00:00

  • EE100 An Approach to Value-Based Pricing for Digital Health Applications in Germany

    Dec 1, 2022, 00:00

  • EE312 Are Methods Used to Generate Utility Values Adequately Included in Technology Assessments for Children and Adolescents? Lessons From HAS Assessments of Manufacturers’ Cost-Utility Analyses

    Dec 1, 2022, 00:00

  • EE256 Budget Impact Analysis of the Introduction of a Novel Gene Expression Biomarker Test for Early-Stage Breast Cancer Patients in Cyprus

    Dec 1, 2022, 00:00

  • HPR12 Treatment Inequities Among Cancer Patients Due to Reimbursement: From the Perspective of 130 Medical Oncologists

    Dec 1, 2022, 00:00

  • HTA167 Transition to New Danish HTA Process

    Dec 1, 2022, 00:00

  • EE73 The Challenge of Demonstrating Cost Effectiveness in Alzheimer's Disease in England: Case Study of a Hypothetical Emerging Treatment

    Dec 1, 2022, 00:00

  • HSD28 Most Common Treatments in Patients With Treatment Resistant Depression Based on European Cohort Study Real-World Evidence

    Dec 1, 2022, 00:00

  • EPH141 Dispensing Patterns for Rabies in Humans: A South African Database Analysis

    Dec 1, 2022, 00:00

  • EE259 US Reference Pricing Impact on Transparency, Pricing, and Access in the EU4 Final

    Dec 1, 2022, 00:00

  • HPR145 Factors of Access to the Market of Innovative Specialties in Algeria: The Case of Hospital Drugs

    Dec 1, 2022, 00:00

  • SA37 Cultural Adaptation and Sociometric Analysis of Aberdeen Varicose Vein Questionnaire

    Dec 1, 2022, 00:00

  • PCR77 Factors to Consider in Deciding on B/Ts Dmards to Manage Inflammatory Arthritis From a Patient Perspective: A Systematic Review

    Dec 1, 2022, 00:00

  • HTA69 Delay of Innovative Oncology Treatments - Case From Bulgaria

    Dec 1, 2022, 00:00

  • RWD133 Assessing the Impact of Bisphosphonates and Selective Estrogen Receptor Modulators in Post-Menopausal Osteoporosis

    Dec 1, 2022, 00:00

  • HTA58 Does NICE’s STA Process Effectively Reward the Value of Double-Branded Oncology Combinations, When Compared to Oncology Monotherapies?

    Dec 1, 2022, 00:00

  • HTA204 HTA Assessment of Adaptive Trials for Oncology Drugs in Europe

    Dec 1, 2022, 00:00

  • HTA162 Assessing Literature Reviews in NICE Single and Multiple Technology Appraisals

    Dec 1, 2022, 00:00

  • CO127 Empirical vs Documented Use of Ceftolozane-Tazobactam for the Treatment of Complicated Infections in French Hospital Settings

    Dec 1, 2022, 00:00

  • EE451 A Narrative Review of The Economic Burden Attributable to Obesity and Overweight in China

    Dec 1, 2022, 00:00

  • HSD18 Access to Healthcare Services During COVID-19 Restrictions in Kazakhstan: A Nationwide Survey on COVID-19 and Lifestyle Changes

    Dec 1, 2022, 00:00

  • RWD147 Demonstrating the Application of Real-World Evidence for Health Technology Assessment Using a Federated Data Network

    Dec 1, 2022, 00:00

  • HPR123 CEE: Brief Overview of Orphan Drug Reimbursement and Selected Clinical Characteristics

    Dec 1, 2022, 00:00

  • EE150 Resource Utilisation in Non-Small Cell Lung Cancer With Brain/CNS Metastases in Europe, Asia, US and Brazil

    Dec 1, 2022, 00:00

  • PCR182 Validity and Responsiveness of EQ-5D-Y in Children With Haematological Malignancies and Their Caregivers

    Dec 1, 2022, 00:00

  • CO82 The Assessment of Surrogate Endpoints and Their Impact on HTA Recommendations

    Dec 1, 2022, 00:00

  • EE432 Budget Impact Analysis of Avelumab + Best Supportive Care (BSC) as First-Line Maintenance Treatment in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) in Ireland

    Dec 1, 2022, 00:00

  • CO13 Evidence Gap Analysis of the Burden of Illness and Treatment of Primary Immune Thrombocytopenia

    Dec 1, 2022, 00:00

  • EE98 Healthcare Resource Utilization and Costs Associated With Previously Treated Advanced Non-Small Cell Lung Cancer Patients Without EGFR Mutations or ALK Rearrangements in Korea

    Dec 1, 2022, 00:00

  • SA80 Data Extraction Templates in Systematic Literature Reviews: How Systematic Are We?

    Dec 1, 2022, 00:00

  • EE582 The Principles of the Economic Evaluation and Public Health Committee (CEESP) Doctrine at the French National Authority for Health (HAS)

    Dec 1, 2022, 00:00

  • CO125 Characteristics of Asthma Patients at GINA's Higher Steps on OCS Treatment: A Cross-Sectional Study in Portuguese Community Pharmacies (EmOCS Study)

    Dec 1, 2022, 00:00

  • HTA112 A Pragmatic Payer-Patient Engagement Framework (PPEF) to Support Ethical Formulary Decision Making Process in Rare Disease (RD) Arena in Commercial Payer Settings in the U.S.

    Dec 1, 2022, 00:00

  • PCR49 Patient Reported Outcomes in Randomized Controlled Trials of Nervous System and Mental Health Disorders: Current Status in India

    Dec 1, 2022, 00:00

  • HTA65 Socio-Economic Determinants of Health Status During COVID-19 Pandemic in Hungary

    Dec 1, 2022, 00:00

  • EE345 Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2-Months Is Cost Effective for the Treatment of HIV-1 in Spain

    Dec 1, 2022, 00:00

  • EE199 Impact on Healthcare Resource Utilization and Indirect Costs Among Individuals With Migraine and Preventive Treatment Failure in France, Germany, Italy, Spain and United Kingdom

    Dec 1, 2022, 00:00

  • RWD1 Factors Affecting Korean Medicine Health Care Use of Functional Dyspepsia in Korea: Analysis of Korea Health Panel Survey 2017

    Dec 1, 2022, 00:00

  • EE444 Еconomic Evaluation of Medical Activity on Fractional Flow Reserve Measurement (FFR) for Functional Assessment of Epicardial Stenoses in Patients With Stable Coronary Heart Disease

    Dec 1, 2022, 00:00

  • HPR51 Identification and Quantification of Implementation Challenges and Costs Associated With Short-Term National-Level Vaccine Switches

    Dec 1, 2022, 00:00

  • EE467 A Review of the Use of Clinical Expert Opinion to Inform Survival Curve Extrapolations in Single Technology Appraisals of New Cancer Drugs by NICE, UK

    Dec 1, 2022, 00:00

  • PCR244 Burden of Myelodysplastic Syndromes Part I: Systematic Literature Review of Epidemiologic and Humanistic Burden

    Dec 1, 2022, 00:00

  • MT22 Qualitative Content Analysis of Secondary Digital Health Terms – Are They Sufficient for Health Outcomes Research Purposes?

    Dec 1, 2022, 00:00

  • RWD4 Health Care Resource Utilization and Cost (HCRU) Among Treatment-Experienced People Living With HIV (PLWH) Switching to Single Tablet Regimen (STR) or Multi-Tablet Regiment (MTR) Triple Therapy Since 2018

    Dec 1, 2022, 00:00

  • EE651 Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in the First-Line Treatment of Patients With Metastatic Triple-Negative Breast Cancer in Greece

    Dec 1, 2022, 00:00

  • EE366 Healthcare Resource Consumption and Related Costs in Patients Under Antiretroviral Therapies: Findings From Real-World Data in Italy

    Dec 1, 2022, 00:00

  • HTA261 Comparison of Molecular Tests for Detection of NTRK Gene Fusions in Patients With Advanced Solid Tumours- A Systematic Review and Economic Evaluation

    Dec 1, 2022, 00:00

  • EE84 Cost of Follow-Up After an Ischemic Heart Disease Event in Patients With Atherosclerotic Cardiovascular Disease in Spain: Results From the Reality Study

    Dec 1, 2022, 00:00

  • EE654 Budget Impact Analysis of Bimekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Greece

    Dec 1, 2022, 00:00

  • EE114 Cost-Utility Analysis of Lung Cancer Screening Combined With Cardiovascular Disease and Chronic Obstructive Pulmonary Disease Screening

    Dec 1, 2022, 00:00

  • CO36 Safety and Efficacy of Augmentation Therapy in Patients with Alpha-1-Antitrypsin Deficiency: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • HTA214 Distributional Cost-Effectiveness Analysis of Lung Cancer Treatments From an NHS England Perspective

    Dec 1, 2022, 00:00

  • PCR234 Patient Preference in Cervical Cancer Screening

    Dec 1, 2022, 00:00

  • EE180 Budget Impact Model of Feiba in the Management of Hemophilia Patients With Inhibitors in the Egyptian Public Healthcare System

    Dec 1, 2022, 00:00

  • EE532 Health Impact Projection of Anti-PD-(L)1 Inhibitors in 13 Cancers Indications in France

    Dec 1, 2022, 00:00

  • EE27 Cost-Effectiveness and Cost-Utility Analysis of Somatrogon Once-Weekly Injectable vs Daily Growth Hormones for Treating Pediatric Growth Hormone Deficiency

    Dec 1, 2022, 00:00

  • CO32 A Systematic Review of Efficacy and Safety of Mitapivat to Treat Hemolytic Anemia in Pyruvate Kinase Deficiency

    Dec 1, 2022, 00:00

  • EE639 Health Care Resource Utilization and Costs Among Persons With a Permanent or Temporary Stoma: A Swedish Register Study

    Dec 1, 2022, 00:00

  • EE522 Budget Impact Model of Anti-Obesity Drugs and Bariatric Surgery in People With Obesity in South Korea

    Dec 1, 2022, 00:00

  • HPR180 Eligibility of Orphan Drugs for Preferential Reimbursement in Egypt

    Dec 1, 2022, 00:00

  • EE514 Treatment-Related and Non-Treatment-Related Out-of-Pocket Costs by Amyotrophic Lateral Sclerosis Disease Stage: A Cross-Sectional Patient Survey and Retrospective Chart Review

    Dec 1, 2022, 00:00

  • RWD160 Racial Disparity in the Treatment of Psoriasis in the US

    Dec 1, 2022, 00:00

  • EE147 Estimating the Causal Effect of Early Use of Erythropoietic Stimulating Agents in Intermediate-1 to Low-Risk MDS Patients: An Application of the Longitudinal Targeted Maximum Likelihood Estimation

    Dec 1, 2022, 00:00

  • RWD16 Role of Real-World Evidence for Treatments Granted Access Under Cancer Drugs Fund: Lessons and Insights From Review of NICE Technology Assessment Reports (2019-2022)

    Dec 1, 2022, 00:00

  • EPH39 Association Between Patient-Physician Communication and Perceived Mental Health Status Among United States Adults With Cancer

    Dec 1, 2022, 00:00

  • HTA89 Androgen Receptor Inhibitors for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

    Dec 1, 2022, 00:00

  • EE274 Orphan Drug Pricing Comparisons in Low-, Middle- and High-Income Countries

    Dec 1, 2022, 00:00

  • PCR66 How Would the Choice of the Multi-Attribute Utility Instrument Affect the Cost-Effectiveness of Cancer Interventions? A Comparison of the FACT-8D and the AQoL

    Dec 1, 2022, 00:00

  • PCR73 Health-Related Quality of Life Outcomes and Associated Factors for Young Adults with Experience of Severe Malaria in Uganda: A Cross-Sectional Comparison with Community Controls

    Dec 1, 2022, 00:00

  • CO19 Adjunctive Albumin Infusion During Large-Volume Paracentesis May Improve Days to Next Hospital Readmission in Cirrhotic Patients

    Dec 1, 2022, 00:00

  • EE209 Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment in Adult Patients Following Complete Resection and Platinum-Based Chemotherapy with Non-Small Cell Lung Cancer (NSCLC) in Finland

    Dec 1, 2022, 00:00

  • HPR185 The International Impact of National Institute for Health and Care Excellence (NICE) Decisions

    Dec 1, 2022, 00:00

  • P40 An Investigation Into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology

    Dec 1, 2022, 00:00

  • CO65 Clinical and Economic Burden Among Patients With Prurigo Nodularis Compared to a Benchmark in Germany: A Real-World-Evidence Claims Data Study

    Dec 1, 2022, 00:00

  • EE495 Cost-Effectiveness Analysis of Adjuvant Atezolizumab Versus Best Supportive Care in the Treatment of Patients With Resectable Early-Stage Non-Small Cell Lung Cancer and PD-L1≥50% Expression

    Dec 1, 2022, 00:00

  • EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants

    Dec 1, 2022, 00:00

  • HTA231 Estimation of Expected Years of Living With Disability in Patients With Non-Small Cell Lung Cancer

    Dec 1, 2022, 00:00

  • EE629 Methodological Concerns in the Medico-Economic Modeling of Adjuvant Management

    Dec 1, 2022, 00:00

  • PCR85 Modifying QALY

    Dec 1, 2022, 00:00

  • CO75 Advanced Multi-Layer, Watertight Closure in Total Joint Replacement: A Retrospective Study

    Dec 1, 2022, 00:00

  • P52 Patient Preferences for Diagnostic Imaging Services Among Underserved and Rural Populations: Blueprint for Value-Based Incentives Incorporating Individual Preference Heterogeneity

    Dec 1, 2022, 00:00

  • PCR70 Avalglucosidase Alfa (AVA) Improves Symptoms and Functioning in Late-Onset Pompe Disease (LOPD) Patients vs Alglucosidase Alfa (ALG): Post-Hoc Analyses of Patient-Reported Outcomes (PROs) From COMET Trial

    Dec 1, 2022, 00:00

  • EE132 Budget Impact Related to Complications on Pre-Bariatric Surgery Patients in Brazilian Public Healthcare System

    Dec 1, 2022, 00:00

  • EE168 Cost-Effectiveness Analysis of Darolutamide Plus Androgen Deprivation Therapy for Patients With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China

    Dec 1, 2022, 00:00

  • HTA29 Digital Health Interventions: A Review of Economic Evaluation Guidelines From Health Technology Assessment Agencies

    Dec 1, 2022, 00:00

  • EPH159 Creating an Online Patient Education Program for Female Population Who Are Over 50 Years Old

    Dec 1, 2022, 00:00

  • PCR289 Building a Practical Strategy and Framework for Diverse and Inclusive Involvement of Patients and Carers in Real World Data Evidence Generation (RWDEG)

    Dec 1, 2022, 00:00

  • MSR57 Study of Time-Course Relationship Using Model-Based Network Meta-Analysis: A Linear Time-Course Model

    Dec 1, 2022, 00:00

  • HTA268 Impact of Independence and Transparency on Drug Availability and Time to Market: EU4 Qualitative and Quantitative Analysis of Pricing, Reimbursement, and Access Processes

    Dec 1, 2022, 00:00

  • EPH152 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A 10-Year Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics

    Dec 1, 2022, 00:00

  • EPH179 The Economic Impact of Diabetic Ketoacidosis (DKA) in People with T1DM at High Risk for DKA: A Structured Literature Review

    Dec 1, 2022, 00:00

  • HSD62 An Analysis of the Status of Newborn Screening Programmes in the European Union and Its Upcoming Developments: What Does This Mean for New Drugs?

    Dec 1, 2022, 00:00

  • EE659 A Novel Modelling Method for Estimating Cost Impact of a Non-Prescriptive Digital Intervention in Type 2 Diabetes

    Dec 1, 2022, 00:00

  • EE107 Ponesimod Indicated for Patients With Active Relapsing Forms of Multiple Sclerosis: A Budget Impact Analysis From the Italian National and Regional Health Care Service Perspective

    Dec 1, 2022, 00:00

  • P36 Can Real-World Evidence (RWE) Drive European, UK, and US Payer Decisions in the Reassessment of Oncology Therapies?

    Dec 1, 2022, 00:00

  • PCR218 Patient Characteristics and Persistence Among Commercially Insured Patients With Multiple Sclerosis Initiating Cladribine Tablets

    Dec 1, 2022, 00:00

  • RWD121 Assessing the Use of Variational Bayes for Large Real-World Data

    Dec 1, 2022, 00:00

  • PCR87 Influence of Nutritional State and the Phase Angle in the Health Related Quality of Life and Clinical Outcome in Head and Neck Cancer

    Dec 1, 2022, 00:00

  • EE270 Economic Burden of Young Onset Parkinson's Disease: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE396 Public Health Impact and Cost-Effectiveness of Herpes Zoster Vaccination for Older Adults in the Netherlands

    Dec 1, 2022, 00:00

  • EPH18 Neovascular Age-Related Macular Degeneration: Prevalence and Treatment With Anti-VEGF From the Perspective of the Italian National Health System

    Dec 1, 2022, 00:00

  • EE162 Cost-Effectiveness of Obinutuzumab Plus Bendamustine and Followed by Obinutuzumab Maintenance Therapy in Chinese Patients With Relapse and Refractory Follicular Lymphoma

    Dec 1, 2022, 00:00

  • HTA41 Modelling Long-Term Treatment Effects for Chronic Progressive Conditions

    Dec 1, 2022, 00:00

  • EE642 Economic Impact Before and After Expensive Drug Reimbursement With Diabetic Macular Edema in South Korea

    Dec 1, 2022, 00:00

  • EPH118 Healthcare Systems Sustainability and Resilien Creating an Index

    Dec 1, 2022, 00:00

  • EE557 Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome With Constipation in China

    Dec 1, 2022, 00:00

  • PCR76 Do We Really Need a Study Looking at That? A Best-Worst Scaling Study Assessing Methodological Research Priorities According to the Patient Preference Research Community

    Dec 1, 2022, 00:00

  • EPH195 Psychometric Evaluation of the Hungarian Version of Oxford Capabilities - Mental Health Questionnaire

    Dec 1, 2022, 00:00

  • PCR20 Diversity of Patient Support Programs for Severe Asthma Treated with Biologic Therapies – A Systematic Literature Review

    Dec 1, 2022, 00:00

  • PCR22 Measurement Properties of 15-Item Singapore Caregiver Quality of Life Scale (SCQOLS-15) in Family Caregivers of Patients With Heart Diseases

    Dec 1, 2022, 00:00

  • EE223 Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients With Advanced Follicular Lymphoma: A Cost Analysis

    Dec 1, 2022, 00:00

  • RWD115 Modelling the Effect of Multi-Indication Treatment in Patients With Multimorbidity Using Population-Scale Linked Electronic Health Records for Healthcare Policy and Decision-Making

    Dec 1, 2022, 00:00

  • HTA217 Reimbursement of Drugs for Rare Diseases in Canada: Do Treatment Cost and Cost-Effectiveness Ratio Correlate With Epidemiologic Factors?

    Dec 1, 2022, 00:00

  • PCR198 Contemporary Trends in the Use of Generic Patient-Reported Outcome Measures in Pediatric Clinical Trials: An Analysis of Clinicaltrials.Gov

    Dec 1, 2022, 00:00

  • RWD84 The Role of Real-World Evidence in Cell and Gene Therapy Regulatory and Health Technology Assessment Decisions

    Dec 1, 2022, 00:00

  • MSR123 Use of Real-World Data in Cost-Effectiveness Analysis of Sequential Biologic Treatment for Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • HPR47 Comparison of the Characteristics and Costs of Vulnerable Populations Hospital Stays in France Regarding Their Coverage Type Between 2011 and 2021

    Dec 1, 2022, 00:00

  • EE386 Impact of Publication of the French Commission for Economic and Public Health Evaluation (CEESP) Doctrine on the Conclusions of Its Economic Opinions

    Dec 1, 2022, 00:00

  • HPR156 Payment and Reimbursement Models for Innovative High-Priced Hospital Drugs in the Netherlands: A Survey of Stakeholder's Attitudes and Experiences

    Dec 1, 2022, 00:00

  • EPH178 Impact Assessment of the COVID-19 Pandemic on Varicella Incidence Across Europe Using Digital Epidemiology Methods

    Dec 1, 2022, 00:00

  • HPR91 Disease-Specific Hardship Financing in India: A Pooled Cross-Section Analysis of Inpatient and Outpatient Cases

    Dec 1, 2022, 00:00

  • RWD79 Burden of Hospitalization, Costs and Comorbidities in Medicaid Patients With Veno-Occlusive Disease (VOD): Analysis of National In-Patient Hospital Database

    Dec 1, 2022, 00:00

  • EE624 Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the Vaccination Programme in the UK

    Dec 1, 2022, 00:00

  • P14 The Impact of Long-Term Follow-Up on Mean Survival Estimates From Immuno-Oncology Clinical Trials

    Dec 1, 2022, 00:00

  • HSD32 Early Access in Fran Reasons for Refusals and Impact on Market Access

    Dec 1, 2022, 00:00

  • PCR253 Establishing Content Validity of Three New Patient Reported Outcome (PRO) Measures for Use in HIV Long-Acting Oral Antiretroviral Therapy (LA-OART) Clinical Trials

    Dec 1, 2022, 00:00

  • EPH184 A Systematic Review of the Burden of Critical Limb Ischemia (CLI) Among Patients With Peripheral Arterial Disease in Japan

    Dec 1, 2022, 00:00

  • MSR3 A Novel Approach for Minimizing Immortal Time Bias in Observational Studies

    Dec 1, 2022, 00:00

  • EE450 The Burden of Intraoperative Hypotension in Patients Undergoing High-Risk Noncardiac Surgery and the Role of a Machine Learning-Derived Algorithm to Optimize Its Management: What Are We Missing Ignoring Supportive Innovations?

    Dec 1, 2022, 00:00

  • EE41 Healthcare Resource Utilization of Severe, Uncontrolled T2LOW and Non-T2LOW Asthma in Finland During 2018-2021

    Dec 1, 2022, 00:00

  • EE127 Evidence and Uncertainty in an Iterative Decision-Making Framework

    Dec 1, 2022, 00:00

  • RWD163 Age-Related Cataract: Patient Characteristics and Real-World Treatment Patterns in the United States

    Dec 1, 2022, 00:00

  • HPR54 Patient Impact of Transferring Hospital-Only Medicines Dispensing to Community Pharmacies: A Longitudinal Prospective Study

    Dec 1, 2022, 00:00

  • EPH165 Inequalities in Health Care Attention of Severely Malnourished Children in Remote and Conflicts Zones

    Dec 1, 2022, 00:00

  • EE278 Resource Utilization and Caring Cost of People Living With Human Immunodeficiency Virus (PLHIV) in Saudi Arabia: A Tertiary Care University Hospital Experience

    Dec 1, 2022, 00:00

  • EE603 Economic Evaluation of C5 Inhibitors in Patients With Paroxysmal Nocturnal Haemoglobinuria – A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE59 Assessing Economic Cost of Treatment of an Episode of Malaria and Its Effect on the Well-Being of Households in Comé District Health (CDH), South-West Benin

    Dec 1, 2022, 00:00

  • PCR92 Treatment Preference of Moderate or Severe Hemophilia a Patients in Taiwan

    Dec 1, 2022, 00:00

  • PCR137 A Psycho-Onco Emotional Anxiety (POEM) Framework and Application to Understanding Emotional and Psychological Burden of Living with Cancer

    Dec 1, 2022, 00:00

  • MSR65 Survival Estimates Using Hazard Ratios Derived From Network Meta-Analyses: Is More Guidance Needed?

    Dec 1, 2022, 00:00

  • MSR52 Target Trial Emulation (TTE) for Real World Data Analyses to Support HTA Decisions

    Dec 1, 2022, 00:00

  • EPH60 Social and Geographical Inequalities in the Choice of Foot Therapy as Preventive Care of Diabetic Foot Ulcers: A Nationwide Registry Study on Danish Diabetes Patients

    Dec 1, 2022, 00:00

  • MSR43 The Use of Safety-Engineered Devices in Preventing Needle-Stick Injuries: A Budget Impact Analysis

    Dec 1, 2022, 00:00

  • EE494 A Cost-Benefit Evaluation for Trivalent to Quadrivalent Influenza Vaccination Switch for 40+ Years Old Dyslipidemia Patients With and Without Previous Cardiovascular Event in Colombia

    Dec 1, 2022, 00:00

  • EE108 Economic Evaluation of the IGRA Screening Test for the Detection of Micobacterium Tuberculosis Infection: An Analysis for the Italian Health System

    Dec 1, 2022, 00:00

  • EPH14 Prevalence of Depression in Japan and the US Populations Before and During the COVID-19 Pandemic: A Retrospective Observational Study Using Real-World Data

    Dec 1, 2022, 00:00

  • RWD29 Use of Telemedicine Services and Health Outcomes in Hypertensive Patients in Pre- and Post-COVID-19 Periods in the United States

    Dec 1, 2022, 00:00

  • PCR111 Assessing Anxiety and Depression Among Gravidas

    Dec 1, 2022, 00:00

  • EPH122 Healthcare Consumptions in Patient with Early Ageing Disease: Case-Control Study From a National Claims Database

    Dec 1, 2022, 00:00

  • MSR74 Can Artificial Intelligence (AI) Replace a Human Reviewer in Systematic Literature Review (SLR)? Validation of the LIVESTARTTM Tool

    Dec 1, 2022, 00:00

  • HTA35 Should Health Technology Assessment (HTA) Bodies Utilize Living HTA Tools? Validation of LiveSLR® and LiveNMA™ Tools Using ICER’S Class Review in Relapsed Refractory Multiple Myeloma (RRMM)

    Dec 1, 2022, 00:00

  • CO31 Associations Between CDR-Global and Meaningful Outcomes in Patients With Alzheimer's Disease

    Dec 1, 2022, 00:00

  • MT14 How Should Clinical Outcomes Factor Into Purchasing Decisions About Macintosh-Style Laryngoscopes?

    Dec 1, 2022, 00:00

  • CO61 Clinical Profile and Healthcare Resource Use of ANCA-Associated Vasculitis: A Real-World Analysis in Italy

    Dec 1, 2022, 00:00

  • HPR142 The Impact of Cost-Shifting Policies on the Pharmaceutical Sector in Greece During the Financial Crisis

    Dec 1, 2022, 00:00

  • HTA107 Direct Market Access for Medecines: Analysis of Eligible Products in France and Comparison With Current German System

    Dec 1, 2022, 00:00

  • HPR83 Unequal Access of Innovative Dermatology Products Across Canada

    Dec 1, 2022, 00:00

  • EE49 Cost-Effectiveness of Relmacabtagene Autoleucel (ANTI-CD19 AUTOLOGOUS CAR-T CELL IMMUNOTHERAPY PRODUCT) Vs Salvage Chemotherapy for Chinese Relapsed or Refractory Large B-Cell Lymphoma Patients

    Dec 1, 2022, 00:00

  • EE165 Cost-Effectiveness Analysis of Liposomal Formulation of Daunorubicin and Cytarabine (CPX-351) for the Treatment of Adult Patients With Newly Diagnosed Therapy-Related AML or AML With Myelodysplasia-Related Changes in Greece

    Dec 1, 2022, 00:00

  • EE1 Healthcare Resource Utilization and Cost of Treatment-Resistant Depression: A Six-Year Trend and Comparative Analysis in Hong Kong

    Dec 1, 2022, 00:00

  • EPH209 Metformin 15-Year Consumption Analysis in Selected European Countries

    Dec 1, 2022, 00:00

  • PCR68 Systematic Literature Review of Health State Utility Values in Patients With Huntington's Disease: Evidence From the Europe and United States

    Dec 1, 2022, 00:00

  • PCR114 Patient-Voice RWE: Comparative Burden Collected From an Online Social Platform

    Dec 1, 2022, 00:00

  • HTA48 An Integrated Approach to HTA Assessments in the EU: Hype or Hope?

    Dec 1, 2022, 00:00

  • EE600 Cumulative Cardiovascular or Renal Disease (CVRD) Hospital Costs for Type 2 Diabetics Free of CVRD at Baseline: A 5-Year Cohort Study in the SNDS Nationwide Claims Database

    Dec 1, 2022, 00:00

  • SA16 Enhancing Clinical Trial Diversity and Representation Through Data-Adaptive Targeted Learning: A Tale of Lurking Berkson Bias

    Dec 1, 2022, 00:00

  • EPH153 Increased Prevalence of Post-Traumatic Stress Syndrome Among Healthcare Workers During the Coronavirus Epidemic

    Dec 1, 2022, 00:00

  • CO6 Influence of Serum Phosphate on the Predictive Utility of Serum Alkaline Phosphatase for Renal Outcomes in Chronic Kidney Disease Patients – A Prospective Cohort

    Dec 1, 2022, 00:00

  • PCR228 Developing Treatment Attributes for a Patient Preference Survey in Inflammatory Bowel Disease

    Dec 1, 2022, 00:00

  • EE579 Economic and Humanistic Evidence in Early-Stage Hepatocellular Carcinoma (HCC) Post Liver Resection or Ablation – A Systematic Literature Review (SLR)

    Dec 1, 2022, 00:00

  • EE575 Cost-Effectiveness of Low-Dose Computed Tomography Screening for Lung Cancer

    Dec 1, 2022, 00:00

  • PCR129 Demonstrating the Value of RWE Gained From Online Health Platforms: Understanding and Reducing Burden in Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • EPH63 Exploring the Potential Public Health Benefits of a Respiratory Syncytial Virus (RSV) Vaccine Candidate (Ad26.RSV.preF/RSV) Among Individuals Aged 65 Years and Older in the UK: A Preliminary Mathematical Modelling Approach

    Dec 1, 2022, 00:00

  • HPR148 The Impact of Patient Access Schemes on the Access of Innovative Oncology Medicines in Asia-Pacific Region: A Targeted Review

    Dec 1, 2022, 00:00

  • SA13 The Impact of the COVID-19 Pandemic on Collaboration and Innovation in Antiviral Drug Development: A Multi-Stakeholder Systems Dynamics Analysis

    Dec 1, 2022, 00:00

  • Applications of Machine Learning and Artificial Intelligence in Real-World Studies

    Dec 1, 2022, 00:00

  • EE166 Cost-Effectiveness of the Pneumococcal Conjugate Vaccine 10 Versus 13 on Pneumococcal Disease in Children in Sweden

    Dec 1, 2022, 00:00

  • HPR4 ISPOR HEOR Trends Over Time: What Is the Influence of Macro HTA Changes?

    Dec 1, 2022, 00:00

  • HTA50 The Architecture of Clinical Prediction Model Research: A Phased Approach

    Dec 1, 2022, 00:00

  • EE301 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) As First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma (La/mUC) in France

    Dec 1, 2022, 00:00

  • HTA192 Precision Versus Non-Precision Oncology Drug Submissions to the National Centre for Pharmacoeconomics in Ireland

    Dec 1, 2022, 00:00

  • EE24 Health Economic Evaluation of Replacing PCV13 With PCV15 in the Danish Childhood Vaccination Programme

    Dec 1, 2022, 00:00

  • HPR23 A Comparative Analysis of Biosimilar Competition in European Markets of TNF-Alpha Inhibitors

    Dec 1, 2022, 00:00

  • MSR78 Population Attributable Fraction Based on Sufficient Causal Framework for Mediation Settings - Evaluation of Resource Distribution on Prevention and Treatment for Stroke

    Dec 1, 2022, 00:00

  • MT13 A Dynamic Budget Impact Analysis of Surgical Treatment for Obesity in Greece

    Dec 1, 2022, 00:00

  • SA42 The Proliferation of Living Systematic Reviews (LSRS) - Dead on Arrival? A Review of LSR Methodology

    Dec 1, 2022, 00:00

  • SA77 Considerations for Patient Identification and Enrolment for Retrospective Studies for the Collection of Long-Term Follow-up Data

    Dec 1, 2022, 00:00

  • MSR27 Lessons Learned From Successful Real-World Evidence (RWE) Studies Supporting Drug Effectiveness in Regulatory Approvals

    Dec 1, 2022, 00:00

  • HTA243 Health Technology Assessment and Reimbursement of Medical Devices in England, France, and Germany

    Dec 1, 2022, 00:00

  • HTA56 Is Evidence on Environmental Impact Included in Health Technology Assessment and Does It Influence Decision-Making?

    Dec 1, 2022, 00:00

  • HTA83 Role of Quality of Life in Health Technology Assessment Agency Final Recommendations: Insights and Lessons From Review of NICE Technology Assessment Reports (2019-2022)

    Dec 1, 2022, 00:00

  • EPH51 The Health and Economic Burden of Bushfires in Australia Between 2021 and 2030: A Modelling Study

    Dec 1, 2022, 00:00

  • PCR99 Exploring Relative Weighting and Ranking of Potential Bolt-on Item for the Eq-5D-5L-Hk by Pairwise Comparison in Hong Kong Context

    Dec 1, 2022, 00:00

  • CO23 Validating the Results of a Matching Adjusted Indirect Comparison (MAIC) in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2022, 00:00

  • EE232 Evaluate Healthcare Resource Utilization (HCRU) Among Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Active Disease

    Dec 1, 2022, 00:00

  • EE635 Direct Comparison of Prophylaxis Cost in Patients With Severe Hemophilia A With and Without Inhibitors With Hemostatic Agents Versus the Use of Emicizumab in Guatemala

    Dec 1, 2022, 00:00

  • HSD67 Real-World Effectiveness in Hypertension and Hyperlipidemia Collaborative Management Between Pharmacies and Primary Care in Portugal: A Multicenter Quasi-Experimental Pragmatic Controlled Trial (USFarmácia®)

    Dec 1, 2022, 00:00

  • HTA95 Analysis of Neurological Conditions Submissions to the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) From 2001 to 2021

    Dec 1, 2022, 00:00

  • EE515 Cost Per Responder Analysis of Methotrexate Versus Other Therapies in the Treatment of Moderate to Severe Plaque Psoriasis in Italy

    Dec 1, 2022, 00:00

  • CO58 Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib With Capmatinib in Previously Treated Advanced Non-Small Cell Lung Cancer (aNSCLC) With MET Exon 14 (METex14) Skipping

    Dec 1, 2022, 00:00

  • HSD23 Operational Waste Savings on Health in a Value-Based Patient Drug Safety Program

    Dec 1, 2022, 00:00

  • EE354 Budget Impact Analysis of Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis in the UK

    Dec 1, 2022, 00:00

  • HPR174 Social Value Evaluation of Long-Term Care Insurance in Korea: Social Return on Investment Approach (SROI)

    Dec 1, 2022, 00:00

  • CO147 Comparative Efficacy and Safety of Pharmacological Interventions for Managing Sickle Cell Disease Complications in Children and Adolescents: A Systematic Review With Network Meta-Analyses

    Dec 1, 2022, 00:00

  • EE631 Cost Minimization Analysis of the Switch to a New Immunization Schedule With a Hexavalent (DTAP-HBV-HIB-IPV) Vaccine in Algeria

    Dec 1, 2022, 00:00

  • CO141 Using LiveSLR Platform to Evaluate the Impact of Duration of Treatment (DOT) on Progression Free Survival (PFS) in Multiple Myeloma (MM)

    Dec 1, 2022, 00:00

  • EE561 Estimation of the Economic Burden of Renal Complications of Diabetes in Algeria

    Dec 1, 2022, 00:00

  • HSD19 Which Elements Determine Prescribing Decisions for Off-Patent Biological Medicines in Belgium? A Qualitative Study

    Dec 1, 2022, 00:00

  • HPR103 Pricing Negotiations of ASMR IV Drugs in Fran Impact of the Latest LEEM-CEPS Framework Agreement

    Dec 1, 2022, 00:00

  • EE182 Budget Impact Analysis of Metabolic Surgery Compared With Best Medical Care for the Treatment of Comorbid Type 2 Diabetes and Obesity

    Dec 1, 2022, 00:00

  • PCR179 Estimating Health Utilities in Patients with Epilepsy Using the SF-6D

    Dec 1, 2022, 00:00

  • SA18 Development and Application of a Taxonomy on the Beneficial Effects of Oral Anticoagulant Switching in Atrial Fibrillation

    Dec 1, 2022, 00:00

  • EPH53 The Role of Incentives- Parents’ Intention to Vaccinate Their 5- to 11-Year-Old Children with the COVID-19 Vaccine in Israel

    Dec 1, 2022, 00:00

  • EPH203 Estimating the Impact of COVID-19 Pandemic on Gynaecology Treatment in England

    Dec 1, 2022, 00:00

  • SA24 Effects of Navigated rTMS for the Hemiparetic Upper Extremity Motor Function in Stroke Patients – Pilot Study

    Dec 1, 2022, 00:00

  • EPH154 The Connection Between the Lunar Cycles and the Number of Births in Hungary

    Dec 1, 2022, 00:00

  • HTA110 The Value of Real-World Evidence (RWE) in Melanoma in Health Technology Assessment (HTA) Appraisals

    Dec 1, 2022, 00:00

  • HPR146 What Are the Opportunities for Flat Pricing of Innovative Medicines Across the EU4 and UK?

    Dec 1, 2022, 00:00

  • EE344 A Systematic Review: Model-Based Cost-Effectiveness Analyses (CEAs) of Guideline-Directed Disease-Modifying Medical Therapies (GDMT) for Heart Failure with Reduced Ejection Fraction (HFrEF)

    Dec 1, 2022, 00:00

  • HTA125 The Relationship Between Value and Price in the Free-Pricing Period and Post-Assessment Price in Germany: A Case Study in Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • CO62 Prophylaxis Treatment for Patients With Hemophilia A Without Inhibitors: Experience Monitoring Survey on the Use of Damoctocog Alfa Pegol

    Dec 1, 2022, 00:00

  • PCR196 Association of Clinical Response Criteria and Disease Activity Levels With Physical Function and HRQoL in Patients With Active Axial Spondyloarthritis: 16-Week Results From Two Phase 3 Randomised, Placebo-Controlled Studies

    Dec 1, 2022, 00:00

  • RWD9 Real-World Relative Dose Intensity in Patients With Advanced or Metastatic Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors in Sweden

    Dec 1, 2022, 00:00

  • EE275 Personalised Versus Standard Dosimetry for Selective Internal Radiation Therapy in Patients With Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

    Dec 1, 2022, 00:00

  • EE201 Survival Analysis Methods Used in Immuno-Oncology NICE Appraisals

    Dec 1, 2022, 00:00

  • HPR62 Equity and Outcome Events in Patients With Hidradenitis Suppurativa: Exploring Effect Modifiers Associated With HS Diagnostic Delay

    Dec 1, 2022, 00:00

  • P28 Evidence-Informed Deliberative Process for Health Technology Assessment in Spain

    Dec 1, 2022, 00:00

  • MSR90 Moving Beyond QALYs: A Composite Indicator to Measure the Benefit of Hearing Implants

    Dec 1, 2022, 00:00

  • MSR81 Alternative Approaches to the Analysis of Utility Data: Atopic Dermatitis

    Dec 1, 2022, 00:00

  • PCR189 Health-Related Quality of Life in Patients Receiving Oral Anti-Coagulants: A Cross-Sectional Study

    Dec 1, 2022, 00:00

  • HTA223 The Current Status and Challenges of Value Assessment in Prevention and Treatment for Alzheimer’s Disease Dementia in Japan

    Dec 1, 2022, 00:00

  • HSD55 Expanding Vaccine Competencies to Community Pharmacists: Modelling Organizational and Economic Impacts of New Human Papilloma Virus (HPV) Vaccines Pathways in France

    Dec 1, 2022, 00:00

  • CO42 Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Treatment of Anaemia of Chronic Kidney Disease: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • HSD86 Contribution of Clinical Pharmacy Services to the Achievement of Diabetes and Hypertension-Related Quality Measures Among Medicare Patients

    Dec 1, 2022, 00:00

  • EPH40 Polyconsultant Patient: A Dynamic Definition for Users Attending Primary Care Emergency Services

    Dec 1, 2022, 00:00

  • HPR65 Prevalence as a Driver of Treatment Cost for Drugs in the Rare Disease Field in Italy

    Dec 1, 2022, 00:00

  • EPH156 Treatment Patterns and Characteristics of People With Newly Diagnosed Major Depressive Disorder Across the Komodo Claims Database 2018-2020

    Dec 1, 2022, 00:00

  • SA41 Kinesiophobia After Returning to Play in Football

    Dec 1, 2022, 00:00

  • SA63 Communicating Complex Methodology Via Infographics: A MAIC Case Study

    Dec 1, 2022, 00:00

  • EPH55 The Prevalence of Obesity and Its Implications in China: A Narrative Review of Literature

    Dec 1, 2022, 00:00

  • HSD105 Cost Savings Benefits of Operational Waste Minimization in a Care Program by Cohorts of Babies on Treatment With Palivizumab

    Dec 1, 2022, 00:00

  • Projecting the Economic Impact of Compensating Living Kidney Donors in the United States: Cost-Benefit Analysis Demonstrates Substantial Patient and Societal Gains

    Dec 1, 2022, 00:00

  • EE676 Impact of Using Innovative Antineoplastic Drugs on Cancer Mortality in Russia

    Dec 1, 2022, 00:00

  • EE377 Healthcare Utilization and Costs Among Acutely Hospitalized Older Adults

    Dec 1, 2022, 00:00

  • EE362 Evaluating the Cost-Effectiveness of Refluxstop as a Treatment for Refractory Gastroesophageal Reflux Disease (GORD)

    Dec 1, 2022, 00:00

  • HSD35 Healthcare Resource Utilization (HCRU) in Treatment of Patients With Localized/Locally Advanced Prostate Cancer (LPC/LAPC) in a Portuguese Comprehensive Cancer Center (PCCC)

    Dec 1, 2022, 00:00

  • MSR80 Impact of Donor Ferritin Testing on Iron Deficiency Prevention and Blood Availability in Fran A Cohort Simulation Study

    Dec 1, 2022, 00:00

  • EE72 Magnetic Resonance Imaging-Based Prostate Cancer Screening: Differences in the Cost-Effectiveness Using Evidence From Diagnostic Cohorts Versus Screening-by-Invitation Trial

    Dec 1, 2022, 00:00

  • HSD41 Development of 'Quality of Care for Patients With Advanced Illnesses (QCPAI)' Instrument for Measuring the Quality of End-of-Life Care From Patients’ Perspective

    Dec 1, 2022, 00:00

  • HSD66 The Association Between Patients’ Socio-Demographic Characteristics and Biologic Treatment Initiation: Real-World Evidence From a 14-Year Cohort of Ulcerative Colitis Patients in Israel

    Dec 1, 2022, 00:00

  • PCR161 Being Active Is Not Enough – Combination of Physical Activity, Sedentary Behaviour and Sleep Characteristic Shows More Positive Effect on Infertility Related Quality of Life in Women Undergoing Art

    Dec 1, 2022, 00:00

  • RWD140 Benefits and Challenges of Deterministic, Probabilistic, and Patient-Mediated Approaches to Linking Patients’ Clinical Trial Data (CTD) and Their Real-World Data (RWD)

    Dec 1, 2022, 00:00

  • EE537 Cost-Effectiveness of Cemiplimab in Patients With Advanced Basal Cell Carcinoma (aBCC) Who Progressed on or Are Intolerant to a Hedgehog Inhibitor (HHI) in Italy

    Dec 1, 2022, 00:00

  • EE412 HBA1C Point-of-Care Testing for Diabetes Control in Low-Income Remote Areas: A Cost-Parity Analysis

    Dec 1, 2022, 00:00

  • EE610 Economic Investment for Saving a Year of Life Following the Israeli Government's Actions in the First Year of the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • EPH56 Trends in Human Papillomavirus (HPV) Vaccine Coverage Rates (VCR) in Fran A Claims Data Study

    Dec 1, 2022, 00:00

  • CO33 A Systematic Literature Review (SLR) of Comparative Efficacy Measures in Randomized Controlled Trials (RCTS) of Adjuvant Treatment in Localized Renal Cell Carcinoma (RCC)

    Dec 1, 2022, 00:00

  • MSR121 Clinical Meaning of the Family-Reported Outcome Measure (FROM-16): A Novel Dimension of Real-World Data

    Dec 1, 2022, 00:00

  • MSR115 Comparison of Statistical Models to Address Ceiling Effect in Utility Scores: A Simulation Study

    Dec 1, 2022, 00:00

  • P8 Role Preferences in Medical Decision Making: Implications for Health Preference Research

    Dec 1, 2022, 00:00

  • SA72 Comparing EQ-5D-5L, Propr, Sf-6D and TTO Utilities in Patients With Chronic Skin Diseases

    Dec 1, 2022, 00:00

  • P22 Value of Information - Consolidated Health Economic Evaluation Reporting Standards: A Checklist Extension

    Dec 1, 2022, 00:00

  • CO101 Burden of Post-Stroke Spasticity: A Real-World Data Analysis in Italy

    Dec 1, 2022, 00:00

  • HSD109 Predictors of Saudi Arabian Pharmacists’ Intent to Provide Medication Counselling

    Dec 1, 2022, 00:00

  • RWD53 Recurrence of Major Adverse Cardiovascular Events (MACE) in Patients Who Had a Prior Myocardial Infarction (MI): An Analysis Based on German Claims Data

    Dec 1, 2022, 00:00

  • EPH188 The Burden of Cancer Among Enrollees Insured Through Commercial Plans in the US (2019-2020)

    Dec 1, 2022, 00:00

  • MSR40 A Comparison of the Performance of a Range of Trial-Level Surrogacy Methods

    Dec 1, 2022, 00:00

  • MT4 Study Design Recommendations in ISO Standards for High-Risk Medical Devices: A Systematic Review of the HORIZON2020 Core-MD Project

    Dec 1, 2022, 00:00

  • EE21 Costs of Hemophilia in Ukraine

    Dec 1, 2022, 00:00

  • EE307 Costs of Treating Soft Tissue Sarcomas and Infantile Fibrosarcoma in Pediatric Patients in Turkiye: A Delphi Panel Study

    Dec 1, 2022, 00:00

  • EE497 Healthcare Resource Utilization and Costs by Cardiovascular Risk Level: Results From the Latino Study

    Dec 1, 2022, 00:00

  • EE425 Economic Modeling of Web Embolization vs Coiling vs Stent-Assisted Coiling for the Endovascular Treatment of Unruptured Intracranial Aneurysms

    Dec 1, 2022, 00:00

  • SA55 Literature Review and Meta Analysis of Alternative Autologous Vein in Below Knee Lower Limb Surgical Bypass in Patients With Critical Limb Ischemia Pad

    Dec 1, 2022, 00:00

  • EE83 Cost-Effectiveness Analysis of an Active Transcutaneous Bone Conduction Implant for Patients With Conductive or Mixed Hearing Loss or Single-Sided Deafness in Turkey

    Dec 1, 2022, 00:00

  • EE339 Budget Impact Analysis of Insulin Glargine-300U/Ml (GLA-300) for Treatment of T1DM and T2DM in Algerian Setting

    Dec 1, 2022, 00:00

  • CO41 Systematic Literature Review of the Survival, Humanistic and Economic Impact of Systemic Corticosteroid Use

    Dec 1, 2022, 00:00

  • EE333 Evaluating the Long-Term Clinical, Societal, and Economic Outcomes of Ofatumumab vs Teriflunomide/Interferon Β-1A and the Impact of Early vs Delayed Ofatumumab Initiation in Relapsing Multiple Sclerosis Patients in Greece

    Dec 1, 2022, 00:00

  • CO43 The Role of Different Biomarkers in the Prognosis of COVID-19 Infection

    Dec 1, 2022, 00:00

  • EE205 Cost-Effectiveness of Adherence Intervention for Tuberculosis Treatments in South Korea Using Discrete Event Simulation Model

    Dec 1, 2022, 00:00

  • EE303 Distribution and Predictors of Haemophilia-Related Direct Medical Cost in the United Kingdom: Analysis of Data From the CHESS I and CHESS II Burden of Illness Studies

    Dec 1, 2022, 00:00

  • EPH71 Factors Associating With the Severity of Soccer Injury Among Men and Women Professional Teams

    Dec 1, 2022, 00:00

  • EE146 Cost-Effectiveness of Axicabtagene Ciloleucel Versus Other CAR T-Cell Therapies in the Treatment of Diffuse Large B-Cell Lymphoma in France

    Dec 1, 2022, 00:00

  • PCR18 An Exploratory Retrospective Social Listening Study to Identify Patient Experiences Associated With Cutaneous Lupus Erythematosus (CLE)

    Dec 1, 2022, 00:00

  • HTA184 Investigating How Orphan Drug Manufacturers Can Optimize Clinical Trial Design so Patients across Geographies Can Access Life-Saving Innovations

    Dec 1, 2022, 00:00

  • SA7 Reduced Health Care Resource Utilisation and Costs Following a Switch From Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in COPD Patients in a Real-World Primary Care Setting in England

    Dec 1, 2022, 00:00

  • HSD82 Real-World Assessment of Antiplatelet Treatment Therapies for Patients With Acute Coronary Syndrome (ACS) in the United Kingdom

    Dec 1, 2022, 00:00

  • HTA66 Price Increases of Prescription Drugs in Sweden – In Which Cases Are They Approved?

    Dec 1, 2022, 00:00

  • EE217 Population Genomic Screening for Tier 1 Genomic Applications: A Cost-Effectiveness Analysis

    Dec 1, 2022, 00:00

  • EE534 Economic Evaluations of HIV-1 Disease in South Africa – A Targeted Literature Review

    Dec 1, 2022, 00:00

  • HTA249 Method in the Madness – Acceptance of Indirect Evidence in Joint Clinical Assessments

    Dec 1, 2022, 00:00

  • CO120 Evidence Gap Analysis of the Burden of Illness and Treatment of Pemphigus Vulgaris and Foliaceus

    Dec 1, 2022, 00:00

  • PCR255 The EQ Health and Wellbeing (EQ-HWB) and the Eq Health and Wellbeing Short (EQ-HWB-S) as an Outcome Measure in Mental Health and Well-Being: A Comparison to the EQ-5D-5L, EQ-5D-3L and the Short Warwick-Edinburgh Mental Well-Being Sca ...

    Dec 1, 2022, 00:00

  • PCR291 Preferences for Key Features of Gonadotropin-Releasing Hormone Analogues Among Women With Endometriosis in the United States

    Dec 1, 2022, 00:00

  • HTA239 The Challenge of Confidential Commercial Arrangements in Health Technology Assessment: How Often Do They Feature in NICE Technology Appraisal Evaluations?

    Dec 1, 2022, 00:00

  • EE361 Cost-Effectiveness Analysis of Ribociclib Versus Abemaciclib in the First-Line (1L) Treatment of Postmenopausal Women With HR+/HER2- Advanced Breast Cancer (ABC)

    Dec 1, 2022, 00:00

  • SA79 Association Between Antibiotic Exposure and Survival Among Patients Diagnosed With Advanced Melanoma or Advanced Non-Small Cell Lung Cancer (NSCLC) Treated With Immune Checkpoint Inhibitor (ICI) Therapy

    Dec 1, 2022, 00:00

  • EE268 Per-Member Per-Month (PMPM) Expenditure Value in Oncology: Updating a Focused Literature Review

    Dec 1, 2022, 00:00

  • EE214 Modelling Cost Determinants for Treating Metastatic Castration-Resistant Prostate Cancer: An Italian National Healthcare System's Perspective Cost Analysis

    Dec 1, 2022, 00:00

  • An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure

    Dec 1, 2022, 00:00

  • HTA250 Health Technology Assessment Policy and Guideline Changes in the EU-5 During the COVID-19 Pandemic Era: An Insight Into Trends and Drivers

    Dec 1, 2022, 00:00

  • Award Winners

    Dec 1, 2022, 00:00

  • EE22 Average CET Limit: Is It Possible to Introduce a Single CET for the Whole EEA?

    Dec 1, 2022, 00:00

  • MSR47 A Stepwise Approach for Assessing the Feasibility of Population-Adjusted Indirect Treatment Comparisons

    Dec 1, 2022, 00:00

  • HPR152 Impact of Brexit-Induced Changes to Regulatory Approval on UK Access to Medicines

    Dec 1, 2022, 00:00

  • RWD98 Variation in COVID-19 Length of Stay Due to Social Factors in the US – Estimation Using Integration of CDC/ATSDR's Social Vulnerability Index (SVI) and Healthcare Claims Data

    Dec 1, 2022, 00:00

  • EE491 Real-World Costs, Health Care Resource Utilization (HCRU), and Outcomes Among Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US

    Dec 1, 2022, 00:00

  • A Comparison of Seven Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies

    Dec 1, 2022, 00:00

  • PCR109 Optimism, Social Support and Psychosocial Impact Among Breast Cancer Survivors: The Mediating Effect of Resilience

    Dec 1, 2022, 00:00

  • HPR184 Uncertainties Around Tumour Agnostic Therapies in Europe: Barriers and Facilitators of Patient Access

    Dec 1, 2022, 00:00

  • CO104 Real-World Impact of a Prescription Digital Therapeutic on Retention in Treatment and Relapse Indicators in Patients With Opioid Use Disorder

    Dec 1, 2022, 00:00

  • EE598 Heterogeneity in Cost-Effectiveness of SGLT2IS Versus DPP4IS According to Baseline Characteristics: A Model-Based Analysis

    Dec 1, 2022, 00:00

  • SA1 The Use of Multi-Criteria Decision Analysis (MCDA) to Support Decision-Making in Healthcare: An Updated Systematic Literature Review

    Dec 1, 2022, 00:00

  • EPH198 Assessing the Validity of Netherlands Linked Routine Healthcare Resource Utilisation Data in the Investigation of Single-Inhaler Triple Therapy Effectiveness (INTREPID Trial)

    Dec 1, 2022, 00:00

  • HPR39 Access to Orphan Drugs in Hungary

    Dec 1, 2022, 00:00

  • PCR171 Considerations for Successful Implementation of Patient-Reported Outcomes in Real-World Evidence Generation: Interviews With Patients and Stakeholders

    Dec 1, 2022, 00:00

  • EPH111 Causes of Medication Administration Errors in a University Hospital in Brazil

    Dec 1, 2022, 00:00

  • MSR59 Replication and Extrapolation From RCTs to Observational Data to Predict Treatment Effects: Why, What, How

    Dec 1, 2022, 00:00

  • EE167 The Socioeconomic Impact of Disability Progression in Multiple Sclerosis: A Retrospective Cohort Study of the German Neurotransdata (NTD) Registry

    Dec 1, 2022, 00:00

  • PCR273 Examining the Quality of Life Among Women With Cervical Cancer

    Dec 1, 2022, 00:00

  • HPR36 Evaluating Patient Preference Information in Regulatory Decision-Making

    Dec 1, 2022, 00:00

  • MSR23 Health Economic Evaluations Alongside New Clinical Trial Designs – Results of an International Expert Panel Workshop

    Dec 1, 2022, 00:00

  • EE558 Cost-Effectiveness of Direct Transfer of Acute Ischemic Stroke Patients to Angiography Suite

    Dec 1, 2022, 00:00

  • CO153 Mind-Body Modalities for Healthcare Workers in the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • EE158 Economic Burden of Cervical Cancer in Bulgaria

    Dec 1, 2022, 00:00

  • CO86 Clinical Outcomes of Diabetic Macular Edema Patients Treated With Faricimab and Aflibercept: A Subcohort Analysis of 20/50 or Worse Visual Acuity Across Faricimab Phase 3 Clinical Trials

    Dec 1, 2022, 00:00

  • P27 Rationing in an Era of Multiple Tight Constraints: Is Cost-Utility Analysis Still Fit for Purpose?

    Dec 1, 2022, 00:00

  • PCR46 Assessing the Mental Health of Secondary School Students in the Light of COVID-19

    Dec 1, 2022, 00:00

  • CO49 3D Visualisation Systems: Advantages for Cataract Surgery

    Dec 1, 2022, 00:00

  • EE55 Comparative Cost-Utility Analysis of Budesonide and the Six Food Elimination Diet (SFED) for the Prophylaxis of Patients With Eosinophilic Esophagitis (EoE) in the Austrian Setting

    Dec 1, 2022, 00:00

  • HPR64 Opportunities and Challenges for Innovative Drugs in China

    Dec 1, 2022, 00:00

  • HTA85 Possible Impact of Orphan Threshold Reduction to 20 Million Euro in the Framework of Early Benefit Assessment and Reimbursement Price in Germany

    Dec 1, 2022, 00:00

  • OP18 Applicability of Appraisal Tools of Real-World Evidence in Health Technology Assessment: A Literature Review and Content Analysis

    Dec 1, 2022, 00:00

  • EE330 Productivity Losses Associated with Spinal Muscular Atrophy (SMA) in Adult Patients in Sweden Not Treated With Disease Modifying Therapies: A Population-Based Study

    Dec 1, 2022, 00:00

  • RWD136 User Profile, Strip Use Habits, and Benefits of the Freestyle Libre System: A Repeated Cross-Sectional Survey of Community Pharmacies in Portugal

    Dec 1, 2022, 00:00

  • HSD21 Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced/Metastatic Breast Cancer (ABC): Testing Patterns, Prescribing Behavior, and Treatment Option Perceptions Among U.S. Oncologists

    Dec 1, 2022, 00:00

  • HTA216 Assessment of Key Drivers of Economic Evaluations for Digital Health and Medical Technologies: Insights and Lessons From Review of NICE Medical Technology Assessment Reports (2010-2022)

    Dec 1, 2022, 00:00

  • PCR24 The Humanistic and Economic Impact of Fibrodysplasia Ossificans Progressiva on Primary Caregivers: Results From an International Burden of Illness Survey

    Dec 1, 2022, 00:00

  • HTA255 Recommendations on the Use of Artificial Intelligence and Machine Learning in Systematic Literature Reviews Submitted as Part of the Evidence Package in Health Technology Assessment

    Dec 1, 2022, 00:00

  • PCR223 Functional Class and Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Findings From a Real-World Study in the US

    Dec 1, 2022, 00:00

  • HPR45 Medical Quality Indicators Trends During the Coronavirus Pandemic in Israel: Meuhedet Health Services Real Data Analysis and Future Conclusions

    Dec 1, 2022, 00:00

  • HTA98 Distribution of the Positive Added Medical Benefit According to the Early Access Status and the Potential Public Health Interest– Analysis of the French HTA Body Opinions (HAS Transparency Committee)

    Dec 1, 2022, 00:00

  • HSD40 Development of the Patient-Focused Heart Failure Screening Questionnaire to Support a Predictive Heart Failure Algorithm in Patients Implanted With a Cardiac Electronic Device

    Dec 1, 2022, 00:00

  • EPH57 Epidemiology of Alopecia Areata Across Global Regions – A Systematic Literature Review

    Dec 1, 2022, 00:00

  • HTA20 Safety and Cost Analysis of Image-Guided Functional Endoscopic Sinus Surgery in China

    Dec 1, 2022, 00:00

  • HTA120 National Health Technology Assessment in Turkey After a Decade: Are Key Principles Followed?

    Dec 1, 2022, 00:00

  • CO53 Real-World Clinical Outcomes and Efficiency of a New Steerable Sheath Technology for Radio-Frequency Ablation in Chinese Patients with Atrial Fibrillation

    Dec 1, 2022, 00:00

  • MSR30 Linguistic and Psychometric Validation of the “Cognition” Bolt-on Version of the Japanese EQ-5D-5L (EQ-5D-5L+C) by Adding a Cognitive Dimension for the Elderly

    Dec 1, 2022, 00:00

  • EPH90 The 2010 HIV Outbreak Among People Who Inject Drugs in Athens, Greece Could Have Been Prevented If the 2009 Undetected HCV Outbreak Had Been Detected. What Would Have Been the Savings If There Was an Outbreak Detection System?

    Dec 1, 2022, 00:00

  • HPR141 Modelling the Impact of Pricing Exceptions and Protections on Pharmaceutical Expenditure in Greece

    Dec 1, 2022, 00:00

  • EPH167 Proportions of Avoidable GP Visits in Fran Findings From a National Claims Database

    Dec 1, 2022, 00:00

  • PCR287 The Social Burden of the Caregivers of Alzheimer's Disease Patients in Egypt

    Dec 1, 2022, 00:00

  • CO116 Cardiovascular Safety of Glimepiride: An Indirect Treatment Comparison of Cardiovascular Safety Outcome Trials of DPP4 Inhibitors

    Dec 1, 2022, 00:00

  • EE26 Costs of Illness of Atypical Hemolytic Uremic Syndrome (aHUS)

    Dec 1, 2022, 00:00

  • EE246 Real-World Costs and Health Care Resource Utilization (HCRU) Among Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US

    Dec 1, 2022, 00:00

  • EE187 Healthcare Resource Utilization in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients With Commercial Insurance Coverage in the US

    Dec 1, 2022, 00:00

  • EE118 Capturing Patient Value in an Economic Evaluation

    Dec 1, 2022, 00:00

  • EE429 Cost-Effectiveness and Budget Impact Analyses of Enzalutamide for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer in Mexico

    Dec 1, 2022, 00:00

  • EPH117 Coinfections in COVID-19 Patients in India: A Systematic Review

    Dec 1, 2022, 00:00

  • HTA86 Health Technology Assessment in Hospitals: A Systematic Review on Methods and Practices

    Dec 1, 2022, 00:00

  • PCR3 Assessing Concept Saturation and Sample Representativeness When Using Social Media Data to Inform Concept Elicitation Studies

    Dec 1, 2022, 00:00

  • EE411 Cost-Utility of Nabiximols for the Management of Spasticity Due to Multiple Sclerosis in Switzerland

    Dec 1, 2022, 00:00

  • MSR45 Challenges in Extrapolation When There Are Multiple Health Outcomes

    Dec 1, 2022, 00:00

  • RWD11 Effectiveness Analysis of CPOE Implementation in Preventing Duplicate Medication: An Evidence From a Single Medical Center in Taiwan

    Dec 1, 2022, 00:00

  • HTA181 Cost-Utility Evaluation of Mammography Screening Program in Taiwan: Considering Costs Related to False Positive Results

    Dec 1, 2022, 00:00

  • PCR6 Real-World Outcomes Among Episodic Migraine Patients with Migraine Preventive Medications in China: Results From the Chinese Adelphi Disease Specific Programme

    Dec 1, 2022, 00:00

  • HPR20 Comparative Analysis of Expenditure on Pharmaceuticals in Czechia and Slovakia – How to Understand the OECD Statistics

    Dec 1, 2022, 00:00

  • HTA245 NICE Immuno-Oncology Appraisals: Comparison of Progression-Free Survival and Overall Survival Analysis Methods and Critique

    Dec 1, 2022, 00:00

  • CO161 Comparison of Clinical Outcomes in De Novo Versus Relapsed/Progressed Advanced Non-Small Cell Lung Cancer Patients Without EGFR Mutations or ALK Rearrangements

    Dec 1, 2022, 00:00

  • PCR141 Patient and Caregiver Perceptions Around the Treatment and Quality of Life Impact of Colorectal Cancer: A Social Media Listening Study

    Dec 1, 2022, 00:00

  • HTA191 Health Technology Assessment in Gree Evaluation of Current Status and Prospects

    Dec 1, 2022, 00:00

  • RWD165 Impact of Armodafinil and Modafinil on Shift Work and Associated Metabolic Disorders

    Dec 1, 2022, 00:00

  • CO47 Medical and Non-Medical Reasons for Discontinuation of Anti-TNF Agents Among Patients With Ulcerative Colitis in Real-World Setting: A Systematic Review

    Dec 1, 2022, 00:00

  • EE125 The Association Between Body Weight During Late Adolescence and Direct Medical Costs Further in Life

    Dec 1, 2022, 00:00

  • CO50 Efficacy and Safety of Itolizumab for the Treatment of Coronavirus Disease (COVID-19): A Systematic Literature Review

    Dec 1, 2022, 00:00

  • Another Step Toward Hepatitis C Elimination: An Economic Evaluation of an Irish National Birth Cohort Testing Program

    Dec 1, 2022, 00:00
  • «
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36 (current)
  • 37
  • 38
  • 39
  • 40
  • »